• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Study Points to Improved PFS in Prostate Cancer Patients on Statin Therapy

Article

The study conducted by researchers at Dana-Farber Cancer Institute, and published in JAMA Oncology, found a siginificant increase in progression-free survival in men who initiated statin therapy along with androgen deprivation for their prostate cancer.

Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy (ADT) for prostate cancer had a longer time in which their disease was under control than did men who didn't take statins, a clinical trial led by Dana-Farber Cancer Institute investigators shows.

In a study published online today by JAMA Oncology, the researchers report that men who had been taking statins since the start of androgen deprivation therapy went a median of 27.5 months before their disease began to worsen, compared to 17.4 months for men who didn't take statins. The trial involved 926 patients, 70% of whom had their disease progress during a 6-year period.

Read the complete news on EurekAlert!: http://bit.ly/1cap5Cy

Related Videos
5 experts are featured in this series
3 experts are featured in this series.
3 experts are featured in this series.
1 expert is featured in this series.
Nihar Desai, MD, MPH
Dr Toon Van Gorp
Andrew Kuykendall, MD, Moffitt Cancer Center
Barry Byrne, MD
Giulio Cossu, MD
Dr Toon Van Gorp
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.